Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2013

View Archived Issues

Novel antibody-drug conjugate for drug-resistant blood cancer tested in preclinical studies

Gilead Sciences presents further clinical data on Stribild

Scripps Research Institute designs dual JNK3/LRRK2 inhibitor

Effective treatment of pancreatic ductal carcinoma xenografts with CBL-0137

Final results of the IMPACT trial of the TLR9 agonist MGN-1703 reported

Sanofi discovers novel FGFR inhibitors

DBV Technologies completes enrollment in VIPES study of peanut allergy

Researchers present phase II results for famitinib in nasopharyngeal carcinoma

Margetuximab well tolerated and active in phase I solid tumors trial

Secukinumab demonstrates superiority to Enbrel in head-to-head phase III study

Bayer begins phase III trial of BAY-94-9027 in children with hemophilia A

Novartis and Biological E to deliver typhoid and paratyphoid vaccines to developing world

Capricor and Nile Therapeutics sign merger agreement

Bayer discloses new FGFR inhibitors for cancer

Sanofi presents novel cannabinoid CB2 receptor ligands

Santaris Pharma licenses Locked Nucleic Acid technology to RaNA Therapeutics

Researchers in the U.K. patent new agents for bacterial infections

EMA accepts MAA for new insulin glargine biosimilar product

Oramed begins patient enrollment in phase IIa trial of ORMD-0801

La Jolla Pharmaceutical begins dosing in phase II trial of GCS-100 in chronic kidney disease

Scientists at Receptos synthesize novel GLP-1 receptor modulators

Phase II study of C. difficile vaccine initiated in Japan

GSK files supplemental NDAs for combination of dabrafenib and trametinib in metastatic melanoma

Novavax commences phase I trial of A(H7N9) influenza vaccine candidate

AstraZeneca enters oncology collaboration with Cambridge medical research institutions

FDA clears Signum Dermalogix's IND application for SIG-990 in rosacea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...